Literature DB >> 29616510

First clinical isolation report of Shewanella algae from the stools of a patient with acute enteritis in Spain.

E Fernández-Fernández, A J Martín-Rodríguez, M Hernández, J M Navarro-Marí, U Römling, J Gutiérrez-Fernández1.   

Abstract

We report a case of acute enteritis caused by Shewanella algae in a cirrhotic patient. Biochemical identification systems revealed to be insufficient to identify the Shewanella isolate at the species level, thus requiring 16S rRNA and gyrB partial gene sequencing. Even if co-infection by Clostridium difficile could not be ruled out, this is, to our knowledge, the first report of acute enteritis caused by Shewanella algae in Europe.
© The Author 2018. Published by Sociedad Española de Quimioterapia.

Entities:  

Mesh:

Year:  2018        PMID: 29616510      PMCID: PMC6159372     

Source DB:  PubMed          Journal:  Rev Esp Quimioter        ISSN: 0214-3429            Impact factor:   1.553


INTRODUCTION

More than 50 species conform the Shewanella genus. Among them, Shewanella algae, Shewanella putrefaciens, Shewanella haliotis and Shewanella xiamenensis can cause disease in humans with the former causing it more often [1]. The reason that explains the prominence of these species to cause disease, and S. algae being most abundant, are unknown. S. algae are a halophilic Gram-negative rod with a distinctive biochemistry: non-glucose fermenting, cytochrome oxidase positive, nitrate reduction test positive, catalase negative and H2S producer. It can be found all over the world especially in seawater, aquatic animals and sediments. This microbe can cause disease in human beings. Case reports from the literature include soft tissue infections as preponderant, but also bacteremia, otitis and arthritis, among others [2]. Most of the cases come from warm coastal areas. Acute enteritis cases are scarce and have been reported in association with Escherichia coli as another pathogen [3] and as a chronic diarrhea case [4]. We present a case of acute enteritis that included S. algae.

CASE REPORT

We report the case of a 69 years old patient with liver cirrhosis, ischemic heart disease, high blood pressure and two admissions in the last two months. He lives in an urban area in southern Spain, 67 km away from the coast with his wife, retired for several years. Contact with wild animals, recent trips to the coast, consumption of unprocessed food, or contact with water or algae had not been reported. The patient arrived at the emergency room with an acute onset, non-bloody diarrhea that had begun 7 days ago. In the next few hours, his condition deteriorated as he had developed shock, acute kidney injury, metabolic acidosis and hyperkalemia. He was then admitted to the ICU. After receiving adequate life support and empiric antibiotic therapy consisting of ciprofloxacin plus metronidazole, he recovered and was transferred to the general Gastroenterology ward from where he was discharged. Stools samples obtained in the emergency room came back positive for S. algae and Toxin (A+B) Clostridium difficile. The S. algae isolate grew on all growth culture media that are commonly used for the isolation of enteropathogenic bacteria as well as on non-selective media like blood agar and in chromogenic medium specific for the isolation of uropathogens (Uriselet 4, BioRad, Madrid, Spain) (figure 1). The isolate was also found to be ornithine decarboxylase positive, indole negative, unable to produce acid from sucrose, and resistant to colistin. It was able to grow in 6.5% NaCl, to cause hemolysis and mucoid colonies in blood agar. S. algae grew at 42ºC and were identified by mass spectrometry MALDI-TOF (Matrix-Assisted Laser Desorption/Ionization, Bruker Daltonics, Madrid, Spain) (score 2.16). It was not identified by API 20NE (bioMérieux®, Marcy-l’Etoile, France) or MicroScan Walkaway (Beckman Coulter, L’Hospitalet de Llobregat, Spain).
Figure 1

Growth of Shewanella algae on culture media (A = CIN, B = XLD, C= selenite broth, D= Hecktoen, E = MacConkey, and F = blood agar) for enteropathogenic bacteria.

Growth of Shewanella algae on culture media (A = CIN, B = XLD, C= selenite broth, D= Hecktoen, E = MacConkey, and F = blood agar) for enteropathogenic bacteria. As S. algae and S. haliotis cannot be clearly differentiated on the basis of their biochemical characteristics or by MALDI-TOF [5], a molecular characterization of the isolate was conducted. Partial sequences of the 16S rRNA and gyrB genes were obtained after PCR amplification with the primer pairs 8F (AGAGTTTGATCCTGGCTCAG) / 1492R (GGTTACCTTGTTACGACTT) [6], and SW-GYRB-F (GAAGTGGCKATGCAGTGGAA)/SW-GYRB-R (CGRCRAATACCACAGCCRAG) [7], respectively. Both sequences were deposited in the GenBank sequence database (NCBI) under the accession numbers KY774312 (16S rRNA) and KY774313 (gyrB), and the phylogenetic relationships of the isolate, hereafter designated as G1, were reconstructed (figure 2). Of note, 16S rRNA sequencing revealed to be insufficient to provide identification at the species level (figure 2A). As shown in figure 2B, the taxonomical position of G1 falls univocally within the S. algae clade for the gyrB reconstruction.
Figure 2

Bayesian phylogenetic trees of isolate G1 and reference strains based on partial 16S rRNA sequences (1406 nt, Hasegawa-Kishino-Yano distance model, invariant sites) (A) and gyrB (597 nt, Tamura and Nei model with equal base frequencies, gamma distribution) (B). Accession numbers are given in parentheses. Maximum likelihood trees showed the same topology. Numbers at the nodes are the Bayesian posterior probability after 5x106 generations and bootstrap after 1000 replicates. The scale bar indicates the number of substitutions per site.

Bayesian phylogenetic trees of isolate G1 and reference strains based on partial 16S rRNA sequences (1406 nt, Hasegawa-Kishino-Yano distance model, invariant sites) (A) and gyrB (597 nt, Tamura and Nei model with equal base frequencies, gamma distribution) (B). Accession numbers are given in parentheses. Maximum likelihood trees showed the same topology. Numbers at the nodes are the Bayesian posterior probability after 5x106 generations and bootstrap after 1000 replicates. The scale bar indicates the number of substitutions per site. Antibiogram performed by E-Test in Mueller-Hilton medium and aerobiosis using an inoculum matching a 0.5 McFarland turbidity standard revealed the following MICs (mg/L): ampicillin (0.125), ciprofloxacin (0.094), trimethoprim-sulfamethoxazole (0.19), cefotaxime (0.125), gentamicin (0.138) and colistin (3). The patient had another hospital admission due to acute diarrhea secondary to C. difficile infection one month after the reported incidence. A stool sample obtained one month later without the patient having signs of infection came back negative for S. algae.

Ethical statement

The study protocol was carried out in accordance with the Declaration of Helsinki. This was a non-interventional study based solely on routine procedures using biological material only for standard gastrointestinal tract infection diagnostics as prescribed by attending physicians. There was no additional sampling or modification of the routine sampling protocol, and data analyses were carried out using an anonymous database. Therefore, ethical approval was considered unnecessary according to national guidelines. The Clinical Management Unit of Infectious Diseases and Clinical Microbiology of the University Hospital Virgen de las Nieves, Spain granted permission to access and use the data.

DISCUSSION

Even though most Shewanella infections are caused by S. algae and to a lesser extent S. putrefaciens, over the last few years, two other species with a pathogenic potential to humans have been reported, namely S. haliotis [8] and S. xiamenensis [9]. A pathogenic potential of S. algae is increasingly recognized worldwide [1]. Since the Shewanella genus is abundant in marine environments, infection often occurs via contact with seawater or consumption of raw seafood. Strikingly, in some other cases like the one presented here, no apparent relationship to such risk factors exist. This pathogen has been identified in opportunistic infections in patients on peritoneal dialysis, with neoplastic disease, tuberculosis and hepatobiliary disease like the case we have presented [5]. While we cannot rule out a simultaneous infection with C. difficile, it is worth noting that the patient had already tested positive for C. difficile infection in a recent admission. At any rate, we were unable to find other S. algae plus C. difficile acute diarrhea cases in the literature. Sometimes, automated systems used in microbiology laboratories cannot yield a reliable identification of Shewanella spp. Thereby, it is necessary to resort to molecular analyses involving the sequencing of more than one gene, as in the case reported herein, since 16S rRNA sequencing and MALDI-TOF mass spectrometry may not be enough to discriminate at the species level. There are no previous S. algae infection cases reported in our area. However, it is important to know its potential to cause severe gastrointestinal disease in immunocompromised patients in order to identify it readily. It is also worth highlighting the need for conducting accurate species identification given the limitations even of modern, up-to-date identification techniques.
  8 in total

1.  Molecular characterization of a catalase-negative methicillin-susceptible Staphylococcus aureus subsp. aureus strain collected from a patient with cutaneous abscess.

Authors:  Michael W Ellis; Ryan C Johnson; Katrina Crawford; Jeffrey B Lanier; D Scott Merrell
Journal:  J Clin Microbiol       Date:  2013-10-16       Impact factor: 5.948

Review 2.  Shewanella algae and Shewanella putrefaciens: clinical and microbiological characteristics.

Authors:  H M Holt; B Gahrn-Hansen; B Bruun
Journal:  Clin Microbiol Infect       Date:  2005-05       Impact factor: 8.067

3.  Shewanella algae in acute gastroenteritis.

Authors:  S Dey; D Bhattacharya; S Roy; S D Nadgir; A Patil; S D Kholkute
Journal:  Indian J Med Microbiol       Date:  2015 Jan-Mar       Impact factor: 0.985

4.  The Phantom Menace for Patients with Hepatobiliary Diseases: Shewanella haliotis, Often Misidentified as Shewanella algae in Biochemical Tests and MALDI-TOF Analysis.

Authors:  Jung-Hyun Byun; Hyunwoong Park; Sunjoo Kim
Journal:  Jpn J Infect Dis       Date:  2016-08-31       Impact factor: 1.362

5.  Nosocomial peripancreatic infection associated with Shewanella xiamenensis.

Authors:  Zhiyong Zong
Journal:  J Med Microbiol       Date:  2011-05-05       Impact factor: 2.472

6.  Intestinal carriage of Shewanella xiamenensis simulating carriage of OXA-48-producing Enterobacteriaceae.

Authors:  Alberto Antonelli; Domenica Maria Di Palo; Angelo Galano; Sabrina Becciani; Carlotta Montagnani; Patrizia Pecile; Luisa Galli; Gian Maria Rossolini
Journal:  Diagn Microbiol Infect Dis       Date:  2015-02-21       Impact factor: 2.803

7.  Emerging infections: shewanella - a series of five cases.

Authors:  Krishna Kanchan Sharma; Usha Kalawat
Journal:  J Lab Physicians       Date:  2010-07

8.  Shewanella haliotis associated with severe soft tissue infection, Thailand, 2012.

Authors:  Kittiyod Poovorawan; Tanittha Chatsuwan; Narisorn Lakananurak; Jira Chansaenroj; Piyawat Komolmit; Yong Poovorawan
Journal:  Emerg Infect Dis       Date:  2013-06       Impact factor: 6.883

  8 in total
  3 in total

1.  First clinical isolation report of Shewanella xiamenensis from Chinese giant salamander.

Authors:  Yingming Zhu; Ting Yao; Yan Wang; Ziliang Zhao; Xiaowei Yang; Xia Liu; Guangwei Zhao
Journal:  Vet Res Forum       Date:  2022-03-15       Impact factor: 0.950

Review 2.  Shewanella infection in humans: Epidemiology, clinical features and pathogenicity.

Authors:  Keyi Yu; Zhenzhou Huang; Yue Xiao; Duochun Wang
Journal:  Virulence       Date:  2022-12       Impact factor: 5.428

3.  Arcobacter butzleri and intestinal colonization.

Authors:  G Jiménez-Guerra; I Casanovas MorenoTorres; T D Moldovan; J M Navarro-Marí; J Gutiérrez-Fernández
Journal:  Rev Esp Quimioter       Date:  2020-01-02       Impact factor: 1.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.